<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - European and Developing Countries Clinical Trials Partnership Programme (A7-0064/2014 - Vicky Ford) - Tuesday, 15 April 2014</title><meta name="title" content="Verbatim report of proceedings - European and Developing Countries Clinical Trials Partnership Programme (A7-0064/2014 - Vicky Ford) - Tuesday, 15 April 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="15-04-2014" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - European and Developing Countries Clinical Trials Partnership Programme (A7-0064/2014 - Vicky Ford) - Tuesday, 15 April 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2014-04-15-ITM-009-27_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2014-04-15-ITM-009-27_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15-ITM-009-26_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-ITM-009-26_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15-ITM-009-28_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2014-04-15-ITM-009-28_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-15_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-15_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2013/0243(COD)">2013/0243(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0064/2014</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2014-0064_EN.html" class="ring_ref_link">A7-0064/2014</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p></td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2014-04-15-ITM-008-26_EN.html" class="ring_ref_link">PV 15/04/2014 - 8.26</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2014-0366_EN.html" class="ring_ref_link">P7_TA(2014)0366</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 15 April 2014 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.27. European and Developing Countries Clinical Trials Partnership Programme (<a href="/doceo/document/A-7-2014-0064_EN.html">A7-0064/2014</a> - Vicky Ford) </td></tr></table>
<a name="2-544-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Dichiarazioni di voto scritte</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118860.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudette Abela Baldacchino (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. - </span>There is a need to work in partnership with developing countries, such as in sub-Saharan Africa, to tackle the negative impacts of poverty-related diseases, which affect 1 billion people and tragically cause such huge loss of life. The spread of poverty-related diseases has a wider impact on the world and Europe in particular, where many of these illnesses have been eradicated.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Aprovo o presente Relatório, uma vez que apoio os objetivos gerais do Programa EDCTP-2 para acelerar o desenvolvimento clínico de intervenções médicas eficazes, seguras e a preço acessível para o tratamento de doenças relacionadas com a pobreza. Reconheço também a necessidade de trabalhar em parceria com os países em desenvolvimento, tais como a África Subsariana, para fazer frente ao impacto negativo das doenças relacionadas com a pobreza, que afetam mil milhões de pessoas e que, tragicamente, causam uma enorme perda de vidas. Reconheço igualmente o impacto que a proliferação de doenças relacionadas com a pobreza tem em todo o mundo e na Europa em particular, onde muitas destas doenças foram erradicadas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97228.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Pino Arlacchi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted for this report because I believe that the European and Developing Countries Clinical Trials Partnership Programme will accelerate the clinical development of effective, safe and affordable medical interventions for poverty-related diseases. There is a need to develop partnership with developing countries such as sub-Saharan Africa to tackle the negative impacts of poverty-related diseases which affect 1 billion people. Moreover, given the humanitarian aspect of this important sector we need to make sure that the best possible outcomes are achieved. Therefore, coordinating closely with other organisations from public, private and voluntary sectors is also vital, not only to maximise the investments of Members States but also to minimise overlap and duplication.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118709.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Fabrizio Bertot (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La presente relazione punta ad accelerare lo sviluppo clinico di interventi medici efficaci, sicuri e a prezzi accessibili per le malattie legate alla povertà quale obiettivo di massima portata dell' EDCTP2. All'interno del Parlamento europeo è forte la consapevolezza sulla necessità di lavorare in partenariato con i paesi in via di sviluppo, quali ad esempio quelli dell'Africa subsahariana, per far fronte all'impatto negativo delle malattie legate alla povertà (in Europa ormai scomparse da tempo), che colpiscono un miliardo di persone e sono tragicamente causa di ingenti perdite di vite umane. Nonostante si siano registrati già dei risultati apprezzabili con il precedente programma, ritengo che la priorità assoluta debba essere l'uso efficiente delle risorse, per fare in modo di conseguire traguardi degni di nota in tempi ragionevoli. È altresì indispensabile uno stretto coordinamento con le altre organizzazioni dei settori pubblico, privato e del volontariato che hanno obiettivi analoghi, non solo per massimizzare gli investimenti degli Stati membri, ma anche per ridurre al minimo sovrapposizioni e duplicazioni. Rimane dunque un imperativo continuare a lavorare per scoprire vaccini e applicazioni terapeutiche e curative, nonché procedure o processi perfezionati.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96681.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vilija Blinkevičiūtė (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. -</span> Balsavau dėl šio pranešimo, nes juo Parlamentas pritaria ES dalyvavimui kelių valstybių narių bendrai vykdomoje antrojoje Europos ir besivystančių šalių partnerystės klinikinių tyrimų srityje programoje. Šios programos tikslas – paspartinti veiksmingų, saugių ir prieinamų medicininės intervencijos priemonių, skirtų su skurdu susijusioms ligoms gydyti, klinikinį kūrimą. Bendradarbiavimas su besivystančiomis šalimis, pvz., Užsachario Afrikos šalimis, siekiant įveikti neigiamus su skurdu susijusių ligų padarinius, su kuriais susiduria milijardas žmonių ir dėl kurių tragiškai prarandama tiek daug gyvybių, yra būtinas. Taip pat reikia įvertinti ir su skurdu susijusių ligų plitimo poveikį platesniam pasauliui, o ypač Europai, kur daugelis šių ligų buvo panaikintos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-968"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Buduća uloga, dizajn i funkcioniranje javno-privatnih i javno-javnih partnerstva su bili predmet intenzivne rasprave tijekom pregovora o programu Horizon 2020. Europska komisija je u listopadu 2013. prezentirala pakete JPP i JJP kao glavne alate za implementaciju Horizon 2020. te ostvarenje rasta i inovacija u Europi. Istraživački prioriteti Programa partnerstva europskih zemalja i zemalja u razvoju na području kliničkih studija trebaju biti kontrola i iskorjenjivanje bolesti povezanih sa siromaštvom. Nadalje EDCTP2 program će služiti jačanju i razvoju kliničkih testiranja u zemljama u razvoju, pogotovo na području Sub-saharske Afrike. Podržavam ovo izvješće, jer bolesti i epidemije ne poznaju državne granice, a svako ulaganje u medicinu u trećim zemljama moramo smatrati ulaganjem u Uniju.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-984"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Ce texte prévoit le prolongement du partenariat des pays européens et des pays en développement sur les essais cliniques. Il s'agit autrement dit d'un soutien de la recherche clinique et des autres actions luttant contre les maladies liées à la pauvreté dans les pays en développement, notamment le virus du sida, le paludisme et la tuberculose. Une coopération plus étroite avec les pays d'Afrique subsaharienne en particulier sera alors justement mise en place.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-992"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted in favour of this report. The EDCTP partnership aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria, and other poverty related diseases. The focus is on clinical trials in sub-Saharan Africa. Several amendments that my Group submitted on the need to strengthen ethical review committees and the regulatory environment, as well as the need to promote equitable and universal coverage of quality health services, were adopted. My constituents in Wales actively support the improvement of healthcare systems in developing countries.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-996"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> O Programa EDCTP-2 tem como objetivo apoiar intervenções médicas eficazes, seguras e a preço acessível nos países em desenvolvimento, para minorar o impacto negativo das doenças relacionadas com a pobreza, que afetam milhões de pessoas, sobretudo em África. Este programa tem tanto de meritório quanto de essencial num quadro de política de apoio ao desenvolvimento e de combate à proliferação de doenças relacionadas com a pobreza. Porém, e tal como a Relatora, considero que deve haver cuidado na fixação dos objetivos do Programa, de modo a que estes não sejam suscetíveis de manipulação. O objetivo real do programa centra-se na descoberta de vacinas, tratamentos e curas, bem como no desenvolvimento de melhores procedimentos e processos e a sua concretização deve ser a medida do êxito.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-998"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du rapport de ma collègue Vicky Ford, qui prolonge un programme de partenariat des pays européens et en développement sur les essais cliniques. Cette initiative, débutée en 2003 et prolongée dans le cadre du Cadre Horizon 2020, a pour objet d'aider à la mise au point de nouveaux traitements contre les maladies touchant les pays en développement, comme le VIH, la malaria et la tuberculose. Les nouveaux médicaments développés devront être sûrs, efficaces et abordables, afin de répondre aux besoins des pays et populations visées. </p>
<p class="contents">Grâce à ce programme, l'Union montre sa détermination à remplir les objectifs du Millénaire définis par les Nations unies, ce dont je me félicite. Le rapport a été adopté à une large majorité.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-545-999"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Le "Partenariat des pays européens et en développement sur les essais cliniques" a été mis en place en 2003 suite à la crise sanitaire mondiale provoquée par les trois principales maladies liées à la pauvreté – le VIH/sida, le paludisme et la tuberculose. Il s'agit de le prolonger pour 10 ans. </p>
<p class="contents">La rapporteure rappelle que "seulement 10[nbsp ]% des fonds mondiaux consacrés à la recherche sont alloués aux maladies responsables de 90[nbsp ]% des pathologies dans le monde". En conséquence elle propose une liste la plus ouverte possible en matière de financement de recherche de maladies liées à la pauvreté. </p>
<p class="contents">Mais le constat de la recrudescence de ces maladies en Europe n'est expliqué que par les migrations. Or, le retour du paludisme en Grèce par exemple est le symptôme même des politiques d'austérité. Comme seul remède, ce texte prône le renforcement des acteurs privés dans la recherche, par le développement des partenariats public-privé et le respect de la stratégie Horizon[nbsp ]2020. Je ne peux accepter de soumettre la santé au monde marchand, ni dans ces pays ni dans l'Europe sous le joug austéritaire. Je m'abstiens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-546-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. - </span>The EDCTP2 programme helps to reduce the social and economic burden of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe and affordable medical interventions for poverty-related diseases. I have therefore supported this report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-546-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE), </span></span>  <span class="italic">písomne </span><span class="bold">-</span> Program Partnerstva európskych a rozvojových krajín v oblasti klinického skúšania má prispieť k znižovaniu výskytu chorôb súvisiacich s chudobou a zanedbávaných infekčných ochorení, ktoré sa mimochodom môžu ďalej šíriť aj do európskych krajín. Komisia a členské štáty významne finančne prispievajú na výskum chorôb a svojimi aktivitami urýchľujú klinický vývoj účinných, bezpečných a prístupných lekárskych opatrení a liekov, ktoré sú adaptované na špecifiká rozvojových krajín. Táto záslužná činnosť musí spĺňať všetky požiadavky na ochranu ľudských práv. Preto považujem za potrebné posilniť postavenie etických komisií a vytvorenie dostatočných záruk na dodržiavanie ľudských práv pri klinických skúškach. Považujem za absolútne nevyhnutné, aby bol od pacientov pred každým zákrokom pri klinickom skúšaní získavaný informovaný súhlas a aby bol skutočne informovaný a dobrovoľný. Projekty financované z rámcového programu Horizont 2020 nesmú byť v rozpore s Chartou základných práv EÚ a ostatnými medzinárodným dokumentmi, ktorými je Únia viazaná.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-547-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> This report which emerges from the Committee on Industry, Research and Energy is a positive step forward for partnerships programmes between Europe and developing countries. That is why I have voted in favour.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-547-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96694.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rolandas Paksas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. -</span> Balsavau už šį pranešimą. </p>
<p class="contents">Siekiant įveikti neigiamus su skurdu susijusių ligų padarinius būtina bendradarbiauti su besivystančiomis šalimis. Ši Europos ir besivystančių šalių partnerystės klinikinių tyrimų srityje programa yra viena pagrindinių priemonių, užtikrinančių veiksmingų, saugių ir prieinamų medicininės intervencijos priemonių, skirtų su skurdu susijusioms ligoms gydyti, klinikinį kūrimą. Labai svarbu, kad ypatingas dėmesys būtų skiriamas geriausiems ekonominiams pasiūlymams bei glaudesniam bendradarbiavimui su kitomis viešojo ir privačiojo sektorių organizacijomis bei savanoriškos veiklos organizacijomis. Manau, kad reikėtų taikyti lankstų požiūrį į bendrą finansavimą, kad šalys galėtų dalyvauti nepiniginiais įnašais. Svarbu užtikrinti, kad būtų remiami didžiausią potencialą turintys projektai ir pinigai nebūtų skirstomi projektams vien dėl to, kad jie įtraukti į sąrašą. Be to, labai svarbu, kad būtų plečiamas programos dalyvių skaičius ir nuolat teikiama informacija apie finansavimo galimybes.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-548-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Pargneaux (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J’ai voté pour cette décision qui permettra la participation de l’Union à un second programme "Partenariat des pays européens et en développement sur les essais cliniques" mené conjointement par plusieurs États membres. </p>
<p class="contents">Cette décision concerne la participation de l’Union européenne à un second programme "Partenariat des pays européens et en développement sur les essais cliniques" (EDCTP-II) mené conjointement par la Belgique, le Danemark, l’Allemagne, l’Irlande, la Grèce, l’Espagne, la France, l’Italie, le Luxembourg, les Pays-Bas, l’Autriche, le Portugal, la Suède et le Royaume-Uni, ainsi que la Suisse et la Norvège. L’objectif général de l'EDCTP-II est la réduction des effets socioéconomiques des maladies liées à la pauvreté dans les pays en développement, en particulier en Afrique subsaharienne, en accélérant le développement clinique d’interventions médicales efficaces, sûres et abordables pour ces maladies.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-548-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112744.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tonino Picula (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Europska unija ima važnu ulogu na području zdravlja na svjetskoj razini. Gotovo polovinu sredstava za Svjetski fond za borbu protiv HIV/AIDS-a, tuberkuloze i malarije osiguravaju države članice i Europska komisija. Također, njihov udio u svjetsko ulaganje u istraživanja o bolestima povezanim sa siromaštvom i zanemarenim zaraznim bolestima iznosi 22[nbsp ]%. Glavna zapreka održivom razvoju u zemljama u razvoju su bolesti povezane sa siromaštvom koje predstavljaju društveni i gospodarski teret. Važno je primijetiti da navedene bolesti predstavljaju rizik i za građane Europe s obzirom na migracijska kretanja i globalnu mobilnost. Zato je potrebno ubrzati klinički razvoj učinkovitih, sigurnih, pristupačnih, prikladnih i financijski dostupnih medicinskih intervencija za bolesti povezane sa siromaštvom i zanemarene bolesti prilagođenih posebnim potrebama i okolnostima zemalja u razvoju. Podržavam izvješće o Programu partnerstva europskih zemalja i zemalja u razvoju na području kliničkih studija. Slažem se da je potrebno ojačati i proširiti suradnju s javnim i privatnim partnerima čime bi se smanjio društveni i gospodarski teret bolesti povezanih sa siromaštvom u zemljama u razvoju.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-548-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Dato l'aspetto umanitario di questa importante attività, un utilizzo efficiente delle risorse è indispensabile, per fare in modo di conseguire il massimo dei risultati. </p>
<p class="contents">Per massimizzare i risultati, è apprezzabile la proposta di creare un coordinamento stretto con le altre organizzazioni dei settori pubblico, privato e del volontariato, che hanno obiettivi analoghi.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-549-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119434.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dubravka Šuica (PPE), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> O izvješću imam pozitivno mišljenje. Još od uspostavljanja prvog partnerstva 2003. godine, kao rezultata globalne zdravstvene krize prouzročene zbog tri bolesti povezane sa siromaštvom (HIV/AIDS, malarija i tuberkuloza), djeluje se u smjeru regulacije problema bitnih za ograničavanje promatrane problematike. Ponajprije, moramo djelovati tako da obuzdamo socijalni i ekonomski teret siromaštva u zemljama u razvoju, posebice u subsaharskoj Africi, i to ubrzavanjem razvoja učinkovitog, sigurnog i cjenovno povoljnog medicinskog tretmana svim potrebitim pojedincima. Bitno je naglasiti i da se samo 10[nbsp ]% svjetskih sredstava namijenjenih istraživanju bolesti odvaja za bolesti koje su odgovorne za 90[nbsp ]% svih svjetskih patologija. Isto tako, europske istraživačke aktivnosti i programi još su razjedinjeni i ne dostižu svoj potencijal ili se preklapaju, a sposobnost provedbe istraživanja u zemljama u razvoju je nedostatna. Europska unija bitan je čimbenik u istraživanju bolesti povezanih sa siromaštvom i zanemarenih zaraznih bolesti. Komisija i države članice za to područje osiguravaju gotovo četvrtinu (22[nbsp ]%) ulaganja vlada na svjetskoj razini. Isto tako, gotovo polovina sredstava za Svjetski fond za borbu protiv HIV/AIDS-a, tuberkuloze i malarije također je osigurana od strane Komisije i članica.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-549-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> This is a positive proposal for the European and Developing Countries Clinical Trials Partnership (EDCTP), and I voted in favour of the report. The first EDCTP programme (EDCTP-I 2003-2012) is now beyond its funding period and is therefore being extended in order to operate as part of the EUʼs research programme Horizon 2020. The budget for the partnership will be drawn from resources already allocated to Horizon 2020. During negotiations the main political issues to resolve were to avoid separating the budgets into two pots which could have led to a significant underspend, and more importantly, to avoid burdening the programme with too many top-down targets. The majority of these ‘targetsʼ will now be used as indicators in the review, allowing the scientists to just concentrate on their research. As with the other JTI and P2P programmes, Parliament ensured that a separate discharge procedure was in place individually to increase the transparency of EU spending. The agreement also guaranteed the parameters of the mid-term reviews of the programme, and that it will be conducted in line with the overall mid-term review of Horizon 2020.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-550-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Nous approuvons l'objectif général de l'EDCTP-II, qui est d'accélérer le développement clinique d'interventions médicales efficaces, sûres et abordables pour lutter contre les maladies liées à la pauvreté. Elle reconnaît la nécessité de travailler en partenariat avec les pays en développement, tels que les pays d'Afrique subsaharienne, pour combattre les répercussions négatives de ces maladies, qui touchent un milliard de personnes et provoquent de trop nombreux décès. Elle est également consciente des conséquences de la propagation de ces maladies, à l'échelle mondiale et pour l'Europe en particulier, où nombre de ces pathologies ont été éradiquées</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-551-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am votat pentru propunerea de decizie privind participarea Uniunii la un al doilea Program de Parteneriat între UE și țările în curs de dezvoltare privind trialurile clinice, derulat în comun de mai multe state membre. </p>
<p class="contents">Uniunea reprezintă un finanțator important pentru cercetarea în domeniul bolilor asociate sărăciei și al bolilor infecțioase neglijate. Comisia și statele membre contribuie la aproximativ un sfert (22%) din investițiile guvernelor în acest domeniu la nivel mondial. Uniunea este, de asemenea, un actor deosebit de important în materie de sănătate mondială. Comisia și statele membre oferă aproximativ jumătate din creditele Fondului global de luptă împotriva HIV/SIDA, a tuberculozei și a malariei. </p>
<p class="contents">Sprijinirea combaterii bolilor asociate sărăciei ar contribui, de asemenea, la protejarea cetățenilor Uniunii împotriva acestor boli, întrucât mobilitatea globală în creștere (inclusiv turismul), mișcările migratoare și schimbările în distribuția geografică a acestor boli înseamnă că Europa ar putea să se confrunte cu provocări noi sau recurente cauzate de aceste boli. Din păcate, doar 10% din fondurile mondiale destinate cercetării se alocă bolilor care reprezintă 90% dintre patologiile de la nivel mondial. </p>
<p class="contents">Este esențial ca obținerea consimțământului în cunoștință de cauză pentru trialurile clinice efectuate în țările în curs de dezvoltare să aibă loc întotdeauna pe o bază voluntară și în urma unei informări adecvate.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-552-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119431.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ruža Tomašić (ECR), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Učinkovito, sigurno, odgovarajuće, pristupačno i cjenovno prihvatljivo liječenje većine bolesti povezanih sa siromaštvom prilagođeno posebnostima zemalja u razvoju posebno u zemljama supsaharske Afrike, još uvijek ne postoji, a ulaganje u kliničke studije i dalje je nedostatno jer su kliničke studije skupe, a povrat ulaganja zbog tržišnih neuspjeha ograničen. Sukladno tome, podržala sam ovu odluku jer će pridonijeti smanjenju društvenog i gospodarskog tereta bolesti povezanih sa siromaštvom u zemljama u razvoju, ubrzanjem kliničkog razvoja učinkovitih, sigurnih, pristupačnih, prikladnih i financijski dostupnih medicinskih intervencija za bolesti povezane sa siromaštvom i zanemarene bolesti prilagođenih posebnim potrebama i okolnostima zemalja u razvoju.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
